Odevixibat
- TRADE NAME: Bylvay (Albireo)
- INDICATIONS: Treatment of pruritus in patients with progressive familial intrahepatic cholestasis.
- CLASS: Bile acid transporter inhibitor
- HALF-LIFE: 2.4 hours
FDA APPROVAL DATE: 07/20/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Bile acid sequestrant
No human data on use in pregnant persons in order to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes.
Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the
reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
Patients who are exclusively on liquid food should not use odevixibat.
Please login to see the rest of this drug profile
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric